The Form 4 filing, an SEC report of an insider's stock activity, was filed on October 14, 2026. That was two days after the October 12 sale. Meluzio Michael Vincent is vice president and principal accounting officer at Cue Biopharma (CUE).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-12 |
| Date of Latest Transaction | 2026-10-12 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 1,144 |
| Price | $28.05 |
| Total Transaction Value | $32,089.20 |
| Insider | |
| Ticker Symbol | CUE |
| Company | Cue Biopharma, Inc. |
| Insider Name | Meluzio Michael Vincent |
| Insider Title | VP, Prin. Accounting Officer |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 47,817 |
| Position Size Change | 2.34% |
| Filing | |
| Filing Date | 2026-10-14 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of 1,144 shares, reported with transaction code S. The record lists one transaction on October 12, 2026.
What was the average price of the transaction?
The average price was $28.05 per share for the October 12 sale.
How did this transaction affect the insider's holdings?
The sale reduced the reported holdings by 1,144 shares, leaving 47,817 shares owned afterward. The shares sold made up 2.34% of the reported holdings before the sale.
What's the total transaction value?
The total value of the sale was $32,089.20.
Are there any special circumstances around this transaction?
Yes. The transaction information points to a link with covering taxes or paying an exercise price. A stock option gives someone the right to buy shares at a set price, called the exercise price. The filing's footnote text was not provided, so the exact purpose and payment details are unknown. The available information does not confirm that taxes were the sale's only purpose.
For research purposes only; not investment advice.